Prevalence and molecular characteristics of DNA mismatch repair protein-deficient sebaceous neoplasms and keratoacanthomas in a Japanese hospital-based population. (28th April 2018)

• Record Type: Journal Article
• Authors: Kuwabara, Kouki; Suzuki, Okihide; Chika, Noriyasu; Kumamoto, Kensuke; Minabe, Toshiharu; Fukuda, Tomoo; Arai, Eiichi; Tamaru, Jun-ichi; Akagi, Kiwamu; Eguchi, Hidetaka; Okazaki, Yasushi; Ishida, Hideyuki
• Is Part Of: Japanese journal of clinical oncology. Volume 48:Number 6(2018)
• Page Start: 514
• Page End: 521
• Publication Date: 2018-04-28
• Subjects: Lynch syndrome -- Muir-Torre syndrome -- sebaceous neoplasms -- keratoacanthoma -- mismatch repair deficiency -- immunohistochemistry; Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyy055
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract : The screening of Muir-Torre syndrome-associated cutaneous neoplasms for identifying patients with Lynch syndrome may be limited. Mismatch repair protein deficiency in the sebaceous neoplasms was almost caused by somatic alterations. Abstract: Background: Muir-Torre syndrome (MTS) is currently considered as a clinical variant of Lynch syndrome (LS). The clinical significance of the screening of patients with MTS-associated cutaneous tumors for the identification of LS has not yet been established. In addition, the prevalence and molecular characteristics of mismatch repair (MMR) protein deficiency in such tumors has scarcely been investigated in the Japanese population. Methods: Immunohistochemistry (IHC) for MMR proteins (MLH1, MSH2, MSH6 and PMS2) was performed in formalin-fixed paraffin-embedded sections prepared from 16 sebaceous neoplasms (SNs) resected from 13 patients and 32 keratoacanthomas (KAs) resected from 31 patients at our institution between January 2005 and March 2014. Tumors showing MMR protein loss were further subjected to genetic analysis for detecting the presence of germline and/or somatic alterations of the MMR genes to identify the precise molecular mechanisms underlying the protein loss. Results: Among the 16 SNs resected from 13 patients, eight SNs resected from five patients (38.5%) showed loss of expression of MMR proteins (MLH1/PMS2 loss, one patient; MSH2/MSH6 loss, four patients). Genetic analyses showed a pathogenic germline MSH2 mutation in one patient, somatic hypermethylation of the MLH1 promoter region in one patient, and somatic alterations of MSH2 without detectable germline mutations of MSH2 in three patients. None of the KAs examined in the study showed any loss of MMR protein expression. Conclusions: The efficacy of routine screening of cutaneous neoplasms known to be associated with MTS by IHC for MMR proteins to identify LS may be fairly limited. MMR protein loss as determined by IHC in SNs is not always diagnostic of LS, and appears, in most cases, to be a result of somatic inactivation of the MMR genes.